• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >Once-weekly albiglutide in the management of type 2 diabetes: patient considerations
【24h】

Once-weekly albiglutide in the management of type 2 diabetes: patient considerations

机译：每周一次阿比鲁肽治疗2型糖尿病：患者注意事项

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract: This review describes the pharmacologic, pharmacokinetic, and pharmacodynamic properties of albiglutide, as well as its clinical efficacy and safety. Albiglutide is a novel, once-weekly, injectable glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes. The European Commission recently granted marketing authorization for the drug in the European Union and on April 15, 2014, the US Food and Drug Administration approved albiglutide (Tanzeum? [GlaxoSmithKline LLC, Wilmington, DE, USA]) to improve glycemic control in adults with type 2 diabetes. Albiglutide has been studied in Phase I, II, and III clinical trials. In the Phase III clinical trials, known as the Harmony series, weekly dosing of albiglutide demonstrated reductions in fasting plasma glucose, postprandial plasma glucose, and glycated hemoglobin, and was associated with weight loss. In all phases of the clinical trials, albiglutide administered once weekly showed a safety and tolerability profile similar to that of placebo, with mild gastrointestinal-related complaints and injection site erythema being the most commonly encountered adverse effects. Compared with pioglitazone and liraglutide, albiglutide has been shown to be clinically less effective. However, it offers the benefit of weight loss that pioglitazone does not, with fewer gastrointestinal side effects than liraglutide. As guidelines continue to advocate for patient-centered treatment strategies, once-weekly albiglutide will be an important addition to the growing armamentarium of treatment options for adults with type 2 diabetes needing target glycemic control.
机译：摘要：该综述描述了阿比鲁肽的药理学，药代动力学和药效动力学特性，以及其临床疗效和安全性。 Albiglutide是一种新型的每周两次可注射的胰高血糖素样肽1受体激动剂，可用于治疗2型糖尿病。欧盟委员会最近授予了该药物在欧盟的销售许可，2014年4月15日，美国食品和药物管理局批准了albiglutide（Tanzeum？[GlaxoSmithKline LLC，威尔明顿，美国，美国）），以改善成人糖尿病患者的血糖控制。 2型糖尿病。 Albiglutide已在I，II和III期临床试验中进行了研究。在称为Harmony系列的III期临床试验中，每周一次的阿比鲁肽给药证明禁食血浆葡萄糖，餐后血浆葡萄糖和糖化血红蛋白减少，并且与体重减轻有关。在临床试验的所有阶段中，每周一次施用阿比鲁肽显示出与安慰剂相似的安全性和耐受性特征，其中最常见的不良反应是轻度胃肠道相关症状和注射部位红斑。与吡格列酮和利拉鲁肽相比，阿比鲁肽在临床上无效。但是，它提供了吡格列酮没有的减肥益处，并且胃肠道副作用比利拉鲁肽少。随着指南继续倡导以患者为中心的治疗策略，对于需要目标血糖控制的2型糖尿病成年人来说，每周一次的阿比鲁肽将成为不断增长的治疗选择的重要补充。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号